Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis

Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes., Blood, 114, 937, 10.1182/blood-2009-03-209262 Cazzola, 2014, From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms., Blood, 123, 3714, 10.1182/blood-2014-03-530865 Nangalia, 2013, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2., N Engl J Med, 369, 2391, 10.1056/NEJMoa1312542 Michalak, 2009, Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum., Biochem J, 417, 651, 10.1042/BJ20081847 Migone, 1995, Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I., Science, 269, 79, 10.1126/science.7604283 Cabagnols, 2015, Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution., Leukemia, 29, 249, 10.1038/leu.2014.270 Klampfl, 2013, Somatic mutations of calreticulin in myeloproliferative neoplasms., N Engl J Med, 369, 2379, 10.1056/NEJMoa1311347 Villeval, 1997, High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice., Blood, 90, 4369, 10.1182/blood.V90.11.4369 Pikman, 2006, MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia., PLoS Med, 3, e270, 10.1371/journal.pmed.0030270 Akada, 2010, Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease., Blood, 115, 3589, 10.1182/blood-2009-04-215848 Wernig, 2006, Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model., Blood, 107, 4274, 10.1182/blood-2005-12-4824 Li, 2010, JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia., Blood, 116, 1528, 10.1182/blood-2009-12-259747 Tiedt, 2008, Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice., Blood, 111, 3931, 10.1182/blood-2007-08-107748 Hasan, 2013, JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα., Blood, 122, 1464, 10.1182/blood-2013-04-498956 Tefferi, 2014, Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients., Am J Hematol, 89, E121, 10.1002/ajh.23743 Pietra, Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms [published online ahead of print October 9, 2015]., Leukemia Kent, 2013, Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion [published correction appears in PLoS Biol. 2015;13(3):e1002092]., PLoS Biol, 11, e1001576, 10.1371/journal.pbio.1001576 Chachoua, 2016, Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants., Blood, 127, 1325, 10.1182/blood-2015-11-681932 Sangkhae, 2014, The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm., Blood, 124, 3956, 10.1182/blood-2014-07-587238 Passamonti, 2014, JAK inhibitor in CALR-mutant myelofibrosis., N Engl J Med, 370, 1168, 10.1056/NEJMc1400499 Yilmaz, 2006, Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells., Nature, 441, 475, 10.1038/nature04703 Rumi, 2014, JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes., Blood, 123, 1544, 10.1182/blood-2013-11-539098